Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04833816
Other study ID # 2019-48
Secondary ID 2020-004812-81
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 5, 2022
Est. completion date August 4, 2024

Study information

Verified date July 2023
Source Assistance Publique Hopitaux De Marseille
Contact Gary Duclos, MD
Phone 0491965531
Email gary.duclos@ap-hm.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to demonstrate a significant reduction of at least 25% in opioid consumption at 48 hours of management of severe trauma, while demonstrating non-inferiority in terms of analgesia, in a group of patients receiving a continuous infusion of low dose ketamine compared to a placebo group.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date August 4, 2024
Est. primary completion date May 5, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male or female adult - Trauma patient presenting at least 2 lesions in two different regions as defined by the ISS (injury severity score) (Head or neck, Face, Thorax, Abdomen and pelvic contents, Upper limbs or pelvic girdle, Lower limbs, External (any skin surface). - Patient presenting at least two regional disorders classified as moderate to maximum defined by an AIS (Abbreviated Injury Scale)> 1. - Patient having signed an informed consent Exclusion Criteria: - Patients with an indication for deep sedation (intracranial hypertension or acute respiratory distress syndrome). - Patient in whom the infusion could not be started within the first 6 hours of initial treatment. - Patient whose state of consciousness is incompatible with understanding the protocol. - Patient with chronic unbalanced arterial hypertension. - Patient with severe heart failure. - Patient with a BMI> 35 kg / m² or a weight of more than 120 kg. - Patient with chronic analgesic consumption defined by consumption of opioid derivatives for more than a week for an intercurrent illness. - Presence of a history of chronic pain. - Presence of a history of epilepsy. - Presence of a history of psychosis or drug addiction. - Presence of a history of stroke. - Patients with an allergy to the molecule or excipients composing ketamine - Patients with an allergy to the molecule or to the excipients making up sufentanil or paracetamol. - Pregnant or breastfeeding woman. - Patient not understanding French. - Protected adult patient (under guardianship, curatorship or legal protection).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Administration of drug
Administration of ketamin during the 48h after trauma

Locations

Country Name City State
France Service Anesthésie Réanimation - Hôpital nord Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total dose of sufentanil All doses of sufentanil and opiods administration 48 hours
Secondary Total amount of opiods 5 days
Secondary Pain assessment 5 days
Secondary Delirium Scale CAM-ICU (confusion assesment method) 5 days
Secondary Global Quality of life SF-36 score 3 months
Secondary Chronical pain SF-MPQ-2 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04992130 - Sport Concussion Performance-Based Prevention Program N/A
Recruiting NCT05451394 - Prevention of Injury in Military Settings Through the Use of Body Awareness. N/A
Withdrawn NCT03928015 - Evaluation of Dronabinol For Acute Pain Following Traumatic Injury Phase 2
Recruiting NCT04588311 - ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients Phase 3
Recruiting NCT05437575 - Prehospital Analgesia INtervention Trial (PAIN) Phase 3
Recruiting NCT06034834 - Near-Infrared Imaging for Perfusion Assessment of Traumatic Soft Tissue and Skeletal Injuries N/A
Recruiting NCT05568888 - Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) Phase 3
Completed NCT02412982 - Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients Phase 4
Withdrawn NCT01497678 - Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center N/A
Completed NCT05225441 - National Investigation in College and High School Among Adolescents on Health and Substances at the FSEF
Completed NCT03927729 - Use of Methoxyflurane (Penthrox) as an Antalgic in Hospital Trauma N/A
Not yet recruiting NCT06366282 - Pediatric and Caregiver Traumatic Stress Intervention (PACTS) N/A
Not yet recruiting NCT06383650 - Use of 81 vs 325mg of ASA in Treatment of BCVI Early Phase 1
Completed NCT04778332 - Trottinettes Urgences 2019-2020
Recruiting NCT06404177 - Enantyum® IV Versus Piroxen® IM in Emergency Pain Management Phase 3
Recruiting NCT05086757 - Evaluation of Trauma Center-Based Intervention for Adolescent Traumatic Injury Survivors N/A
Completed NCT03628846 - Opioid Use After Traumatic Injury in Adolescents
Active, not recruiting NCT05320445 - A Psychosocial Transitional Group to Improve Adaptation, Coping and Mental Health Outcomes Following Trauma N/A
Completed NCT01771055 - Direct Peritoneal Resuscitation Effects in the Damage Control Patient N/A
Completed NCT01485419 - Characterization of the Early Sex Hormone Milieu Post Injury and Relationship With Resuscitation Requirements and Coagulopathy N/A